The Medicines and Healthcare products Regulatory Agency approves GSK and Vir Biotechnology's sotrovimab antibody treatment, after a clinical trial found that the treatment reduced the risk of hospital admission and death by 79% in vulnerable adults if administered within five days of symptoms developing.
The Medicines and Healthcare products Regulatory Agency approves the sotrovimab made by GSK and Vir Biotechnology named Xerudy, after a clinical trial found it reduced vulnerable adults’ risk of hospital admission and death by 79% and should be given within five days of symptoms developing.
The Medicines and Healthcare products Regulatory Agency approves GSK and Vir Biotechnology'ssotrovimabantibodytreatment, after a clinical trial found thatthetreatmentreduced the risk of hospital admission and death by 79% in vulnerable adultsifadministered within five days of symptoms developing.
